CCL5hi-CD4+ T 细胞 调节巨细胞极化并促进膀癌中免疫治疗反应
Weiming Luo1, Yapeng Wang1, Haitao Wang2
1Daping Hospital CHONGQING China.
Cancer research
|February 18, 2026
概括
研究人员发现了特定的CD4+T细胞 (CCL5hi),可以预测膀癌中免疫检查点抑制剂 (ICI) 治疗的成功. 瘤产生的前列腺素E2 (PGE2) 阻碍这些细胞,导致对ICI治疗的抵抗.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
背景情况:
- 免疫检查点抑制剂 (ICI) 已经彻底改变了癌症治疗,但只对一小部分患者有益.
- 识别生物标志物和理解耐药机制对于提高ICI疗效至关重要.
研究的目的:
- 在膀癌中识别与ICI反应相关的CD4+T细胞群.
- 阐明ICI耐药性背后的机制.
- 探索治疗策略,以提高ICI的疗效.
主要方法:
- 流细胞计和单细胞分析以表征T细胞种群.
- 在体外共同培养试验评估T细胞功能和巨细胞两极分化.
- 对瘤微环境因素的分析,包括前列腺素E2 (PGE2).
主要成果:
- 一个独特的CCL5hi-CD4+ T细胞群体,表达类似记忆的激活标记,与膀癌中的积极ICI反应有很强的相关性.
- 这些CCL5hi-CD4+ T细胞通过通过CCL5/CCR1信号传递驱动M1样巨细胞极化来促进抗瘤免疫力.
- 瘤衍生的PGE2被确定为抑制免疫刺激CCL5hi-CD4+T细胞分化的一个关键因素,导致ICI耐药性.
结论:
- CCL5hi-CD4+ T细胞是骨髓介导抗瘤免疫的关键驱动因素,也是ICI反应的潜在生物标志物.
- 来自瘤的PGE2破坏了CCL5hi-CD4+T细胞分化,导致免疫逃避和ICI耐药性.
- 向PGE2或增强CCL5hi-CD4+T细胞功能可能代表改善ICI在膀癌中的疗效的新疗法策略.
相关概念视频
01:27Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
01:22T Cell Activation and Clonal Selection
16.5K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
16.5K